Anti-ntb-a antibodies and related compositions and methods
AssigneeSeattle Genetics, Inc.
InventorsTimothy S. Lewis, Che-Leung Law
Life of this patent
Estimating the term…
Abstract
Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.
Claims3
A method of treating a patient having a cancer characterized by NTB-A (SLAMF6) expression, the method comprising:
- administering to the patient an effective regime of a monoclonal antibody that specifically binds to human NTB-A, wherein the antibody comprises a CDR-H1 amino acid sequence as shown in SEQ ID NO:
- 5 or SEQ ID NO:
- 11, a CDR-H2 amino acid sequence as shown in SEQ ID NO:
- 6 or SEQ ID NO:
- 12, a CDR-H3 amino acid sequence as shown in SEQ ID NO:
- 7 or SEQ ID NO:
- 13, a CDR-L1 amino acid sequence as shown in SEQ ID NO:
- 8 or SEQ ID NO:
- 14, a CDR-L2 amino acid sequence as shown in SEQ ID NO:
- 9 or SEQ ID NO:
- 15, and a CDR-L3 amino acid sequence as shown in SEQ ID NO:
- 10 or SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.